Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: Basic science, rationale, background and future of denosumab: a RANK ligand inhibitor

Highly Accessed Review

Biology of RANK, RANKL, and osteoprotegerin

Brendan F Boyce* and Lianping Xing

Arthritis Research & Therapy 2007, 9(Suppl 1):S1  doi:10.1186/ar2165

Accesses  

  • Last 30 days: 175 accesses
  • Last 365 days: 1397 accesses
  • All time: 15332 accesses